Biomet Looks Abroad For Revenue Growth In Fiscal 2008
This article was originally published in The Gray Sheet
Executive Summary
Biomet is highlighting growth overseas as a key driver of corporate revenues, and hip and knee reconstruction device sales in particular, reporting 16% top-line expansion for its fiscal fourth quarter (ended May 31)
You may also be interested in...
Orthopedic Surgeons Say Education Funding Is Casualty Of DOJ Agreements
The federal actions against the major orthopedic implant makers last fall have led to a reduction of industry-sponsored medical education, some surgeons say
Physician-Initiated Alert Sparks Zimmer Investigation Of Durom Hip Failures
Zimmer is investigating failures of its Durom hip implants after a prominent joint reconstruction surgeon sent a letter reporting a series of problems with the device to the American Association of Hip and Knee Surgeons
Stryker Ramps Up Compliance Spending, But Predicts Unimpeded Growth
Stryker is raising its stake in compliance activities in response to government scrutiny of its regulatory and sales practices, but the firm does not foresee a major hit to its bottom line